IFN-β1a (recombinant human)

Ligand id: 8339

Name: IFN-β1a (recombinant human)

No information available.
Summary of Clinical Use
IFN-β1a is used clinically to treat relapsing forms of multiple sclerosis [1]. Two brands of recombinant IFN-β1a are available: Avonex® and Rebif®, both of which are produced in Chinese Hamster Ovary cells and are glycosylated peptides.
Mechanism Of Action and Pharmacodynamic Effects
IFN-β1a activates interferon receptors and induces expression of genes involved in antiviral, immunomodulatory and antiproliferative effects. The mechanism of action underlying the therapeutic benefit of IFN-β1a therapy remains unclear.